Bonesupport lands CE Mark for next-gen antibiotic bone graft substitute
February 19, 2013 by MassDevice staff
Swedish orthopedic company Bonesupport touts European regulatory approval for its next-generation Cerament|G resorbable, antibiotic bone substitute.
Swedish orthopedic trauma products maker Bonesupport won CE Mark approval in the European Union for its next-generation Cerament|G injectable antibiotic-eluting bone substitute.
The Cerament|G product is an osteoconductive, ceramic substance designed to promote bone healing while preventing bone infection, or osteomyelitis The resorbable bone graft substitute is designed to remodel into healthy bone within 6-12 months while preventing colonization of microorganisms, especially in cases of deep bone infection.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Mobilizing on the back end of a disaster
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
Navigation
NEWS
Weight loss: GI Dynamics adds centers in Europe
GI Dynamics says another 5 centers in Europe are offering its EndoBarrier weight-loss device for...
Boston Scientific launches U.S. Parkinson's trial, cites interim EU data
Boston Scientific launches a U.S. clinical trial of its Vercise deep-brain stimulation treatment for...
Yale study of Medtronic's Infuse shows it's equivalent to bone graft, but studies were biased
A pair of independent analyses of patient-level data commissioned by a Yale University open data...
J&J's Synthes unit wins $16M ruling in patent fight with Globus Medical
A Delaware jury sides with Johnson & Johnson's DePuy-Synthes subsidiary in a patent spat over 3...
